Case 1: Tki Therapy In Cp-Cml

Case 1: Molecular Testing & Treatment in CP-CML

Targeted Oncology

Case 1: Refractory CP-CML With Multiple Comorbidities

Targeted Oncology

Managing TKI Therapy in CML

Targeted Oncology

Case 1: Ponatinib in Chronic-Phase CML

Targeted Oncology

Treatment of CML with TKI’s

Management of pediatric CP-CML in the TKI era & additional considerations in this patient population

VJHemOnc – Video Journal of Hematology & HemOnc

Case 3: TKI Therapy and Treatment Monitoring in CML

Targeted Oncology

Rationale for TKI Therapy in Relapsed CML

Targeted Oncology

CML as an Ideal Cancer for Targeted Therapy With TKI

Targeted Oncology

CML: Rationale for Mutation Testing and TKI Therapy

Targeted Oncology

Should All Newly Diagnosed CP-CML Patients Start with a 2nd-generation TKI as Frontline Therapy?

Final results of the BFORE trial: bosutinib vs imatinib in CP-CML

VJHemOnc – Video Journal of Hematology & HemOnc

Recent advances in diagnosis & management of Chronic myeloid leukemia (CML) | AFAHD

Medical Learning Hub

CML and pregnancy: Patient and partner considerations

Monitoring Response to TKI Therapy

Debate: Is It Time for Discontinuing TKI Therapy in CML Patients Outside of Clinical Trials?

Phase I study of asciminib in patients with CP-CML carrying the T315I mutation

VJHemOnc – Video Journal of Hematology & HemOnc

When can TKIs be stopped in CML?

Cost-benefit considerations for TKI selection in CML

VJHemOnc – Video Journal of Hematology & HemOnc